Search
Amgen China Web Resources
×

Do you want to link to other websites and leave Amgen.cn?

No, Return to Amgen.cn  Yes, Leave Amgen.cn

You are now leaving Amgen China website. Amgen China takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the China regulatory environment.

×

Do you want to link to other websites and leave Amgen.cn?

No, Return to Amgen.cn  Yes, Leave Amgen.cn

You are now leaving Amgen China website. Amgen China takes no responsibility for the information contained on the Amgen international server or site which you will be accessing. The information you are about to access may not comply with the China regulatory environment.

CHINA NEWS RELEASES

China News Releases



November 10, 2021
Amgen Enters into Strategic Collaboration with Profex to Co-promote Prolia® in China Broad Market

September 17, 2020
Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies

June 19, 2020
Amgen Receives National Medical Products Administration Approval For Prolia® (Denosumab) in China

April 30, 2020
Amgen Reports First Quarter 2020 Financial Results

April 2, 2020
Amgen and Adaptive Biotechnologies Announce Strategic partnership to develop A therapeutic TO prevent or treat COVID-19

March 23, 2020
Amgen and the Amgen Foundation Commit Up to $12.5 Million to Support COVID-19 Relief Efforts

November 22, 2019
Program of Building of High-Quality and Efficient Health Service System and Empirical Study in the Context of Aging Kicked off in Beijing

October 31, 2019
Amgen Enters into Strategic Collaboration with Beigene to Expand Oncology Presence in China

September 26, 2019
Nearly 80% of Chinese Heart Attack Survivors Underestimate the Importance of High Cholesterol Management

September 8, 2019
Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019

May 24, 2019
Amgen Receives Approval For XGEVA® (Denosumab) in China As The First Medicine To Treat Giant Cell Tumor Of Bones (GCTB)

January 24, 2019
Amgen Receives NMPA Approval For Repatha® (evolocumab) In China To Reduce The Risk Of Cardiovascular Events

September 18, 2018
China Charity Federation Launches Repatha® Patient Assistance Program

August 8, 2018
Amgen’s Repatha® (evolocumab) Receives Approval In China As The First PCSK9 Inhibitor For The Treatment Of Homozygous Familial Hypercholesterolemia

March 23, 2018
Amgen Receives Positive CHMP Opinion Recognizing That Repatha® (Evolocumab) Prevents Heart Attacks And Strokes

Sept. 26, 2017
Amgen And Simcere Announce Strategic Collaboration To Co-Develop And Commercialize Biosimilars In China

Sept. 20, 2017
Amgen Foundation Launches Amgen Biotech Experience In China

July. 26, 2017
Amgen-Peking University Study Published in Cell Reveals Why Some T Cells Fail to Fight Cancer

Aug. 27, 2015
FDA Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab)

July. 21, 2015
European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

May. 22, 2015
Amgen Receives Positive CHMP Opinion For Use Of Repatha™ (Evolocumab) For The Treatment Of High Cholesterol

Mar. 1, 2015
Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

Dec. 3, 2014
BLINCYTO is the First-and-Only Bispecific CD19-Directed CD3 T-Cell Engager (BiTE®) Immunotherapy to be Approved by the FDA

Nov. 17, 2014
Amgen Opens Asia Research and Development Center and Establishes Integrated Research and Development Capacity in China

Oct. 9, 2014
Amgen's BiTE® Immunotherapy Blinatumomab Receives FDA Priority Review Designation In Acute Lymphoblastic Leukemia

Aug. 4, 2014
Amgen Announces Phase 3 ASPIRE Trial Of Kyprolis® In Patients With Relapsed Multiple Myeloma Met Primary Endpoint

Sept. 26, 2013
Betta Pharma and Amgen Announce Approval to Establish Planned Joint Venture

Sept. 24, 2013
Amgen and ShanghaiTech University Announce Plans for Amgen China R&D Center to Open on ShanghaiTech Campus

Aug. 7, 2013
Amgen Launches Post-Doctoral Fellowship Program in China

May. 9, 2013
Amgen and Zhejiang Beta Pharma Announce Planned Joint Venture in China